The purpose of the study is to determine whether the drug can improve kidney function compared with placebo. Kidney function will be assessed by measuring how well the kidneys filter waste, using a test called creatinine clearance, during the first few hours after the infusion starts.

After the surgery, eligible infants are randomly assigned to receive the study medication or placebo. The infusion is given over a short period, and blood and urine samples are collected for safety checks and to evaluate kidney performance. The children are then observed for about two days to monitor urine output, fluid balance, and any signs of kidney problems, with follow‑up continuing until the study ends.

During the study, participants will be given either sodium hydrogen carbonate or a comparison solution containing electrolytes, such as sodium chloride, calcium chloride dihydrate, potassium chloride, or magnesium chloride hexahydrate. These comparison solutions include options like Jonosteril Infusionslösung, Sterofundin ISO Infusionslösung, and Ringer-Infusionslösung B. Braun. The study monitors various health outcomes over a 90-day period, including the need for kidney replacement therapy, which refers to treatments like dialysis that perform the work of the kidneys, and changes in creatinine levels, a substance in the blood used to measure how well the kidneys are functioning.

The purpose of the study is to evaluate the safety and effectiveness of a drug called R2R01. This medication is a Relaxin Agonist, which is a type of substance designed to activate specific proteins in the body to achieve a therapeutic effect. During the study, participants will receive either R2R01 or a placebo containing Sodium Chloride via a subcutaneous injection, which is an injection given into the fatty tissue just under the skin.

Participants will be assigned to different groups to receive different doses of the medication or the placebo. The study is double-blind, meaning that neither the participants nor the medical staff know which substance is being administered. The course of the study involves monitoring the participants after their surgery to observe how their kidneys function and to track any side effects that may occur.

Participants in this study will be adults who are in the hospital with sepsis and have developed acute kidney injury. They must have been diagnosed with sepsis within seven days of being admitted to the hospital and must have developed kidney injury within a certain time after the sepsis diagnosis. Participants will need to be receiving medications to support their blood pressure because of the sepsis. The study medication must be given within a specific time window after the kidney injury is diagnosed.

During the study, doctors will measure how well the kidneys are working by checking various blood and urine tests. They will look at substances in the blood called creatinine and cystatin C, which show how well the kidneys are filtering. The study will also track whether participants need kidney replacement therapy, which is a treatment that does the work of the kidneys when they are not working properly. Other measurements will include how many days participants are alive without needing a breathing machine, how long they stay in the intensive care unit, and whether they need to return to the hospital after being discharged. The study will also measure the amount of AZD4144 in the blood to understand how the medication moves through the body.

The purpose of this research is to understand how these two different anesthesia medications affect kidney blood flow in children who need to undergo Magnetic Resonance Imaging (MRI). During the study, children will receive either propofol or sevoflurane while having their MRI scan. Special imaging techniques will be used to look at how blood flows through the kidneys during anesthesia.

The study involves children between 1 month and 14 years of age who already need to have an MRI scan with anesthesia as part of their regular medical care. During the procedure, researchers will measure kidney blood flow and oxygen levels using special MRI techniques. They will also take a blood sample to measure certain kidney-related substances in the blood.

Participants in the study will be randomly assigned to one of two groups. One group will receive nicotinamide, while the other group will continue with the standard care they are already receiving. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the nicotinamide or the standard care, ensuring unbiased results.

The main goal of the study is to determine if nicotinamide can lead to complete recovery of kidney function within 21 days. This will be measured by checking the estimated glomerular filtration rate (eGFR), which is a test that shows how well the kidneys are filtering blood. The study will help understand if nicotinamide can be a beneficial addition to the treatment of acute kidney injury.

The treatment will last for 5 days and will be given to patients who need heart surgery that uses a heart-lung bypass machine (a device that temporarily takes over the function of the heart and lungs during surgery). The study will look at whether these medications can help prevent several complications that can occur after surgery, including acute renal failure (sudden loss of kidney function), breathing problems, and the need for medications to maintain blood pressure.

Patients will receive either the combination of both medications or inactive substances that look the same as the real medications. The study will monitor patients for various side effects and complications for up to 28 days after their surgery. Some of the things being watched for include problems with salt levels in the blood, high blood sugar, infections, and any effects on the heart or brain.

The purpose of the study is to determine if GDC-8264 can help prevent serious kidney-related complications that may occur within 90 days after heart surgery. These complications include death, need for dialysis (a procedure that filters blood when kidneys aren’t working properly), or significant decline in kidney function. The study will also look at how well the kidneys work at different time points after surgery and monitor the development of Chronic Kidney Disease.

During the study, participants will undergo planned heart surgery that requires the use of a cardiopulmonary bypass machine, which temporarily takes over the function of the heart and lungs during surgery. Some participants will receive GDC-8264, while others will receive placebo. The study will monitor kidney function and overall health for 90 days after the surgery.

The purpose of this study is to determine if taking empagliflozin once daily around the time of surgery can reduce the chances of developing acute kidney injury in patients who are having planned heart surgery that involves the use of a heart-lung machine. Some participants in the study will receive empagliflozin, while others will receive a placebo, which looks like the medication but does not contain the active ingredient. This helps researchers understand the true effect of the medication.

Participants in the study will take the medication or placebo for a period of time before and after their surgery. The study will monitor the participants’ kidney function and overall health for up to 90 days following their surgery to see if there is any improvement or change in their condition. The goal is to find out if empagliflozin can help protect the kidneys during and after heart surgery.

Participants in the study will receive either Angiotensin II or Noradrenaline through an intravenous infusion, which means the medication will be delivered directly into the bloodstream. The study will last for a maximum of three days, during which the effects of the treatments on kidney function will be closely monitored. The goal is to determine which treatment is more effective in preventing AKI after heart surgery.

The study will also look at other outcomes, such as the rate of death or the need for dialysis within 90 days, and any long-term changes in kidney function. By comparing these two treatments, researchers hope to find a better way to manage blood pressure and protect kidney function in patients undergoing heart surgery.

The purpose of the study is to evaluate whether the infusion of human serum albumin can help prevent severe AKI in these patients during the first week after the onset of septic shock. Participants in the study will receive either the human serum albumin treatment or a placebo. The study will monitor the participants’ kidney function and overall health for several weeks to assess the treatment’s effectiveness and safety.

Throughout the study, researchers will also track other health outcomes, such as the need for additional organ support, the length of time patients require treatments like mechanical ventilation, and overall survival rates over a 28-day period. The study aims to provide valuable insights into whether human serum albumin can improve outcomes for patients with septic shock and a high risk of AKI.

Participants in the study will receive either the TIN816 treatment or a , which is a substance with no active medication. The treatment is given as a powder that is mixed into a solution and administered through an injection or infusion into the veins. The study will monitor the participants’ kidney function by measuring levels of a substance called serum creatinine in the blood, which helps indicate how well the kidneys are working.

The study will take place over a period of time, with regular check-ups to assess the safety and tolerability of TIN816. Participants will be observed for any side effects and changes in their health, including their vital signs and kidney function. The goal is to determine if TIN816 can effectively reduce the risk of acute kidney injury in patients who have undergone cardiac surgery, compared to those who receive the placebo.

The main goal of the study is to see how well the cell therapy works in helping the kidneys recover after surgery. Participants in the study will receive either the cell therapy or a placebo through an injection. The study will monitor how quickly kidney function returns to normal and will also look at the safety and any side effects of the treatment. The study will take place over a period of time, with regular check-ups to assess the participants’ health and kidney function.

By participating in this study, researchers hope to find a new way to treat acute kidney injury after heart surgery, potentially improving recovery and reducing complications. The study will also gather information on the overall health and recovery of participants, including their time spent in the hospital and any additional treatments they may need. This research could lead to better treatment options for patients experiencing kidney problems after heart surgery.

Participants in the study will receive either the L-Glutamic Acid infusion or a placebo during their surgery. The study will monitor the patients for any increase in a substance called p-creatinine, which is a marker used to detect AKI. Additionally, the study will observe changes in another marker, p-NT-proBNP, which is related to heart function, from the day before surgery to the third day after surgery.

The trial is expected to start recruiting participants in March 2025 and aims to conclude by June 2027. The study is designed to provide valuable insights into whether L-Glutamic Acid can help reduce the risk of kidney injury and heart complications in patients undergoing heart surgery.

Participants in the study will be randomly assigned to receive either TIN816 or a placebo, which is a solution that does not contain the active drug. The study will be conducted in a way that neither the participants nor the researchers know who is receiving TIN816 or the placebo, to ensure unbiased results. The study will last for several weeks, during which time participants will receive the treatment and have their kidney function monitored through various tests. These tests will help determine how well the kidneys are working by measuring substances like creatinine, which is a waste product filtered by the kidneys.

The study aims to gather information on the safety and effectiveness of TIN816 in improving kidney function in patients with SA-AKI. Researchers will also look at other important outcomes, such as the occurrence of any serious kidney-related events and overall health status over a period of time. The results of this study could provide valuable insights into new treatment options for patients suffering from this serious condition.

Participants in the study will receive either the combination of R2R01 and Terlipressin Acetate or just Terlipressin Acetate. The study will last for a period of up to 14 days, during which the medications will be administered through an injection into a vein. The goal is to see how well the combination treatment works in improving kidney function and overall health in patients with Hepatorenal Syndrome – Acute Kidney Injury.

The study will monitor participants for any side effects and changes in their health, including kidney and liver function, over a period of 30 days after starting the treatment. The researchers will also look at how many patients respond positively to the treatment and whether the combination of R2R01 and Terlipressin Acetate offers any additional benefits compared to Terlipressin Acetate alone. This information will help determine the potential of the new treatment approach for patients with this serious condition.

The purpose of the study is to see if using a low dose of argipressin during the liver transplant surgery can help reduce the risk of developing AKI afterward. Participants in the study will receive either the argipressin treatment or a placebo during their surgery. The study will monitor the participants for a period after the surgery to observe any effects on kidney function and other health outcomes.

Throughout the study, various health indicators will be tracked, such as the need for blood transfusions, the use of other medications like norepinephrine, and the overall health status of the participants. The study aims to provide valuable information on whether this treatment can improve outcomes for patients undergoing liver transplants and help prevent complications like AKI.

Participants in the study will be given either dapagliflozin or a placebo, which looks like the real medication but does not contain any active ingredients. The study will take place over a period of time, starting before the surgery and continuing through the hospital stay. Researchers will monitor the participants for any signs of atrial fibrillation or kidney injury, as well as other health outcomes such as heart failure, stroke, and overall safety of the medication.

The study aims to provide valuable information on whether dapagliflozin can be an effective treatment to improve recovery and reduce complications after coronary artery bypass surgery. Participants will be closely observed during their hospital stay and for a period after discharge to ensure their safety and to gather comprehensive data on the effects of the treatment.

The study will compare the effects of ravulizumab with a placebo, which is a substance with no active medication. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The goal is to see if ravulizumab can reduce the risk of kidney problems after surgery. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants in the study will be monitored over a period of time to assess the impact of the treatment on their kidney health. The study will track various outcomes, including the occurrence of kidney injury and recovery, as well as overall health and any side effects. The findings from this study could provide valuable insights into improving care for patients with CKD undergoing heart surgery.

The purpose of the study is to compare how well cilastatin and thiosulfate protect the kidneys during this treatment. Participants will receive either cilastatin or thiosulfate during their surgery. The study will monitor kidney function by measuring levels of a substance called creatinine in the blood, which indicates how well the kidneys are working. The study will also use a scale called the KDIGO scale to assess kidney health. The main focus is on the first week after surgery, but if there are signs of kidney problems, monitoring will continue for up to two weeks.

Throughout the study, researchers will also look at other factors, such as any side effects from the treatments and differences in how the body processes cisplatin between the two groups. The study aims to provide valuable information on which treatment offers better protection for the kidneys during this complex cancer treatment.

The purpose of the study is to evaluate how the treatment affects the heart and overall health of patients during the year following their discharge from the ICU. Participants in the study will receive either Irbesartan or a placebo, and their health will be monitored over the course of a year. The study aims to see if Irbesartan can help reduce the risk of major heart-related events, such as heart attacks or strokes, and improve kidney function in patients who have had AKI.

Throughout the study, researchers will track various health outcomes, including the occurrence of any new episodes of AKI, changes in kidney function, and any heart-related issues. The study will also collect biological samples at the beginning and end of the study to help understand the effects of the treatment. This research is important for finding better ways to support patients recovering from AKI and improve their long-term health outcomes.